Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

1.

Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India.

Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, Mane AA, Bhagat S.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1566-9.

PMID:
15577409
[PubMed - indexed for MEDLINE]
2.

Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.

Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L; Médecins Sans Frontieres.

AIDS. 2006 May 12;20(8):1163-9.

PMID:
16691068
[PubMed - indexed for MEDLINE]
3.

Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.

Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P.

Clin Infect Dis. 2008 Mar 15;46(6):933-40. doi: 10.1086/528861.

PMID:
18271750
[PubMed - indexed for MEDLINE]
Free Article
4.

Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.

French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D; OzCombo 2 investigators.

HIV Clin Trials. 2002 May-Jun;3(3):177-85. Erratum in: HIV Clin Trials 2002 Nov-Dec;3(6):following table of contents.

PMID:
12032876
[PubMed - indexed for MEDLINE]
5.

Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.

Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenal B, Lai AR, Saghayam S, Balakrishnan P, Yepthomi T, Poongulali S, Flanigan TP, Solomon S, Mayer KH.

AIDS Patient Care STDS. 2008 Apr;22(4):337-44. doi: 10.1089/apc.2007.0093.

PMID:
18422462
[PubMed - indexed for MEDLINE]
6.

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.

Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E.

Lancet. 2004 Jul 3-9;364(9428):29-34.

PMID:
15234853
[PubMed - indexed for MEDLINE]
7.

Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.

Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L, Liégeois F, Andrieux-Meyer I, Zekeng L, Calmy A, Mpoudi-Ngolé E, Delaporte E.

Antivir Ther. 2005;10(2):335-41.

PMID:
15865228
[PubMed - indexed for MEDLINE]
8.

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.

Antivir Ther. 2005;10(5):605-14.

PMID:
16152754
[PubMed - indexed for MEDLINE]
9.

Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.

van Oosterhout JJ, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE.

Antivir Ther. 2007;12(4):515-21.

PMID:
17668560
[PubMed - indexed for MEDLINE]
10.

Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.

Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, Audu RA, Araoyinbo ID, Onyewuche JI, Salu OB, Adedoyin JA, Musa AZ.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):65-9.

PMID:
16123684
[PubMed - indexed for MEDLINE]
11.

A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.

Zijenah LS, Kadzirange G, Rusakaniko S, Kufa T, Gonah N, Tobaiwa O, Gwanzura C, Matsikire E, Katzenstein DA.

Cent Afr J Med. 2006 Jan-Feb;52(1-2):1-8.

PMID:
17892232
[PubMed - indexed for MEDLINE]
12.

Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.

Kumarasamy N, Vallabhaneni S, Cecelia AJ, Yepthomi T, Balakrishnan P, Saghayam S, Flanigan TP, Carpenter CC, Solomon S, Mayer KH.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):53-8.

PMID:
16340473
[PubMed - indexed for MEDLINE]
13.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
[PubMed - indexed for MEDLINE]
Free Article
14.

Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.

Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.

Antivir Ther. 2004 Apr;9(2):197-204.

PMID:
15134181
[PubMed - indexed for MEDLINE]
15.

Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.

Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S.

J Med Assoc Thai. 2004 Jul;87(7):760-7.

PMID:
15521230
[PubMed - indexed for MEDLINE]
16.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.

AIDS. 2001 Jul 6;15(10):1261-8.

PMID:
11426070
[PubMed - indexed for MEDLINE]
17.

Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.

Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P.

J Med Assoc Thai. 2006 Sep;89(9):1472-8.

PMID:
17100387
[PubMed - indexed for MEDLINE]
18.

Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.

Torti C, Costarelli S, De Silvestri A, Quiros-Roldan E, Lapadula G, Cologni G, Paraninfo G, Castelnuovo F, Puoti M, Carosi G; BHCC Study Group.

Drug Saf. 2007;30(12):1161-9.

PMID:
18035868
[PubMed - indexed for MEDLINE]
19.

The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.

Barlow-Mosha LN, Bagenda DS, Mudiope PK, Mubiru MC, Butler LM, Fowler MG, Musoke PM.

Afr Health Sci. 2012 Sep;12(3):249-58.

PMID:
23382737
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.

Tsuchiya N, Pathipvanich P, Yasuda T, Mukoyama Y, Rojanawiwat A, Matsubayashi T, Saeng-aroon S, Auwanit W, Matsuyama A, Sawanpanyalert P, Ariyoshi K.

Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):71-82.

PMID:
19323037
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk